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Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor 
rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) 
 
Background: In the phase 2 studies ARIEL2 (NCT01891344) and Study 10 (NCT01482715), rucaparib 
has shown promising clinical activity in pts with HGOC (Shapira-Frommer R et al. Eur J Cancer 
2015;51:S545;abs. 2746; Coleman R et al. J Clin Oncol 2016;34;suppl;abs. 5540). Data from these 
studies were pooled to evaluate the efficacy of rucaparib in pts with BRCA mutated (BRCAmut) HGOC. 
Safety was assessed in pts with HGOC (BRCAmut and BRCA wild-type [BRCAwt] combined). 
Materials and Methods: Pts (n=106) with BRCAmut (88 germline; 13 somatic; 5 origin uncertain), 
relapsed HGOC who received ≥2 prior chemotherapies and enrolled in ARIEL2 Part 1 or 2 (n=64) or 
Study 10 Part 2a (n=42) by 1 Oct 2015 were included in the integrated efficacy analysis. The data 
cutoff dates were 30 Nov 2015 (Study 10) and 29 Feb 2016 (ARIEL2). The integrated safety analysis 
included 377 pts with HGOC who received ≥1 prior chemotherapy (data cutoff dates, 31 Mar 2016 
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 and 29 Apr 2016 for Study 10 and ARIEL2, respectively). All pts received a starting dose of oral 
rucaparib (600 mg BID) in continuous 21- or 28-day cycles until disease progression or other reason 
for discontinuation. 
Results: In the primary efficacy analysis population (n=106), median age was 59 (range, 3384) 
years. Pts received a median of 3 (range, 26) prior chemotherapies. The investigator-assessed 
confirmed objective response rate (ORR) was 53.8% (95% confidence interval [CI], 43.863.5); 8.5% 
of pts had a complete response, and 45.3% had a partial response. ORR in pts with a germline or 
somatic BRCAmut tumor was 53.4% (95% CI, 42.564.1) and 46.2% (95% CI, 19.274.9), respectively. 
ORR was 80.0% (95% CI, 28.499.5) in pts with a tumor BRCA mutation of uncertain origin. ORR in 
pts with platinum-sensitive (n=79), platinum-resistant (n=20), or platinum-refractory (n=7) disease 
was 65.8% (95% CI, 54.376.1), 25.0% (95% CI, 8.749.1) and 0% (95% CI, 041.0), respectively. 
Median duration of response was 9.2 months (95% CI, 6.611.7). In the safety population (n=377), 
the median duration of treatment was 5.5 (range, 0.128.0) months. Common treatment-emergent 
adverse events included nausea (76.9%; grade ≥3, 5.0%), asthenia/fatigue (76.7%; grade ≥3, 10.9%), 
vomiting (46.2%; grade ≥3, 4.0%), and anemia (41.4%; grade ≥3, 24.1%). Grade 3–4 laboratory 
abnormalities included decreased hemoglobin (23.3%), increased ALT (12.5%), decreased 
lymphocytes (9.8%), decreased platelets (6.9%), decreased neutrophils (6.1%), and increased AST 
(4.5%). Increases in ALT or AST normalized over time with continued rucaparib treatment. 
Conclusions: Rucaparib has clinical activity in HGOC tumors with a germline or somatic BRCA 
mutation and an acceptable safety profile in pts with HGOC. The efficacy of rucaparib will be 
compared to standard chemotherapy in a phase 3 study (ARIEL4; NCT02855944). 
